Core Insights - Vivos Therapeutics has released clinical data indicating that its FDA-cleared Daytime-Nighttime Appliance (DNA) provides significant relief for children suffering from ADHD and obstructive sleep apnea (OSA) [1][6] Company Overview - Vivos Therapeutics, Inc. specializes in developing and commercializing treatments for sleep-related breathing disorders, particularly OSA [1][9] - The DNA appliance is the only FDA 510(k) cleared non-surgical, non-pharmaceutical treatment for moderate to severe pediatric OSA in children aged 6-17 [2][10] Market Context - The diagnosed rates of ADHD in the U.S. have increased from approximately 2-3% in the 1980s to over 11% by 2022, while the prevalence of OSA in preschool children rose from 3-9% before 2014 to 13-20% by 2022 [3][4] - There is a strong correlation between pediatric OSA and ADHD symptoms, with up to 95% of pediatric OSA patients exhibiting attention deficits [4][6] Clinical Data Findings - In a recent dataset, children treated with the Vivos DNA appliance reported a 50% decrease in the Pediatric Sleep Questionnaire scores and a 58% decrease in symptoms related to sleep-disordered breathing and ADHD [6][7] - The clinical trial included 55 patients, with 48 completing the study, showing significant improvements in airway volume (+40%) and a reduction in OSA severity by 51.4% [7][8] Treatment Implications - The improvements in OSA and ADHD symptoms may enhance children's academic performance and overall quality of life, with most benefits observed within the first six months of treatment [8]